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1  |  INTRODUC TION
Acetaminophen (ACT; also known as paracetamol) is an effec-
tive and safe analgesic/antipyretic drug, used as early as 1893.1 
Erroneously, phenacetin was preferred to ACT at this time due to a 
perceived greater safety profile; however, it was found to have a role 
in analgesic nephropathy.2 In 1949 it was established that the ther-
apeutic efficacy of phenacetin was due to its metabolite ACT,3 with 
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Abstract
The precise mechanistic action of acetaminophen (ACT; paracetamol) remains de-
bated. ACT’s analgesic and antipyretic actions are attributed to cyclooxygenase (COX) 
inhibition preventing prostaglandin (PG) synthesis. Two COX isoforms (COX1/2) share 
60% sequence structure, yet their functions vary. COX variants have been sequenced 
among various mammalian species including humans. A COX1 splice variant (often 
termed COX3) is purported by some as the elusive target of ACT’s mechanism of 
action. Yet a physiologically functional COX3 isoform has not been sequenced in hu-
mans, refuting these claims. ACT may selectively inhibit COX2, with evidence of a 4.4- 
fold greater COX2 inhibition than COX1. However, this is markedly lower than other 
available selective COX2 inhibitors (up to 433- fold) and tempered by proof of potent 
COX1 inhibition within intact cells when peroxide tone is low. COX isoform inhibition 
by ACT may depend on subtle in vivo physiological variations specific to ACT. In vivo 
ACT efficacy is reliant on intact cells and low peroxide tone while the arachidonic acid 
concentration state can dictate the COX isoform preferred for PG synthesis. ACT is 
an effective antipyretic (COX2 preference for PG synthesis) and can reduce afebrile 
core temperature (likely COX1 preference for PG synthesis). Thus, we suggest with 
specificity to human in vivo physiology that ACT: (i) does not act on a third COX iso-
form; (ii) is not selective in its COX inhibition; and (iii) inhibition of COX isoforms are 
determined by subtle and nuanced physiological variations. Robust research designs 
are required in humans to objectively confirm these hypotheses.
K E Y W O R D S
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phenacetin use subsequently discontinued in the United Kingdom 
(1980) and United States (1983).4 Thereafter, ACT use increased 
markedly, currently used by 60 million people per week in the United 
States.5 ACT has similar functions (i.e., analgesic/antipyretic) to non- 
steroidal anti- inflammatory drug (NSAIDs). Despite their use since 
the late 1800s, the mechanism of action of NSAIDs [inhibition of 
prostaglandin (PG) synthesis] was not elucidated until 1971.6 More 
precisely, NSAIDs exert their action on the cyclooxygenase (COX) 
enzyme.6 Initially, due to ACT’s weak anti- inflammatory and anti-
platelet action it was not thought to inhibit COX.6 However, ACT 
was subsequently found to inhibit COX in the brain.7
The COX enzyme is the catalyst for the rate- limiting steps that 
synthesize PG’s.1,8 COX oxidizes arachidonic acid resulting in the 
production of prostaglandin G2 (PGG2 before peroxidization to 
prostaglandin H2 (PGH2), this compound is metabolized via precise 
enzymatic activities to produce the desired PG.8 Central to defin-
ing the mechanism of action of ACT (and NSAIDs) was the determi-
nation of a second COX isoform in 1991.9– 11 These COX isoforms 
(COX1 and COX2) share 60% structural sequence identity,12 yet 
their expression and function can vary. COX1 has been attributed 
“housekeeping” functions and is constitutively expressed in most 
tissues, maintaining homeostasis (e.g., gastric cytoprotection and 
hemostasis12,13), while, COX2 is inducible, expressed in various 
pathophysiological states (e.g., inflammation12,13). However, the as-
signing and general superficial acceptance of such isoform specific 
functions, likely, oversimplifies these highly complex isoforms and 
is sometimes inaccurate.12 Indeed, there may be some constitutive 
COX2 expression/function14– 17; attributing any in vivo molecule/
biomarker a specific function in complex hosts such as humans must 
be done so with caution, particularly when attempting to determine 
the mechanism(s) of drug action.18,19 Throughout this paper, the use 
of COX refers to the combination of COX1 and COX2 and the in-
dividual isoforms will be named specifically when referring to their 
individual action.
ACT’s mechanistic actions are not fully elucidated and remain 
under investigation.20,21 After the second COX isoform was discov-
ered,9– 11 several further COX variants have been sequenced, in hu-
mans and other mammals22,23; most discussed of these is COX3.24 
Some claim this as the elusive target of ACT’s action20,24– 26 while 
others refute the COX3 hypothesis.22,27– 29 Parallel to the COX3 hy-
pothesis are debates of whether ACT is selective in its COX1 and/
or COX2 inhibition, or not.30,31 Table 1 provides an overview of re-
search that has investigated the in vivo mechanism of action of ACT 
and its proposed target. This paper will discuss the evidence for the 
hypotheses that ACT, with specificity to human in vivo physiology: 
(i) does not act on a third COX isoform; (ii) is not selective in its COX 
inhibition; and (iii) inhibition of COX isoforms are determined by sub-
tle and nuanced biological variations.
2  |  COX3: ACETAMINOPHENS TARGET 
COX ENZ YME?
ACT’s mechanistic action is distinct from traditional NSAIDs,1 with 
weak anti- inflammatory31 and/or antiplatelet action32 alongside 
superior gastrointestinal safety.33 Intuitively, ACT’s COX1/2 inhibi-
tory mechanism of action31,32 has been questioned. Born out of this 
was the plausibility of the existence of an unidentified COX isoform 
being highly sensitive to ACT inhibition.34 Figure 1 displays a visual 
representation of the traditional and proposed (i.e., COX3) ACT/
COX inhibition mechanisms. COX3, an alternatively spliced mes-
senger ribonucleic acid (mRNA) variant of COX1, was found in the 
canine cerebral cortex.24 The fact that this enzyme is not genetically 
distinct and its gene mRNA is identical to COX1 except for the re-
tention of intron 1,32 the naming of this enzyme as COX3 is refuted 
by some.22,29 However, for the purposes of this paper COX3 will be 
used. The catalytic properties of the three COX enzymes (COX1- 3) 
were assessed through PGE2 concentration post exogenous arachi-
donic acid administration in insect cells.24 COX2 demonstrated the 
greatest catalytic activity [COX3 exhibited ~4% of the activity of 
COX224]. Subsequently, COX 1– 3 sensitivity to inhibition via ACT 
was determined; the COX3 enzyme had the lowest IC50 value of the 
three COX enzymes (COX3: 64 µmol·L; COX1: 133 µmol·L; COX2: 
5887 µmol·L) in the presence of 5 µmol·L arachidonic acid.24 At 
30 µmol·L arachidonic acid, ACT’s inhibitory action was reduced, 
only COX3 was inhibited with an IC50 value of 460 µmol·L.
24 Here 
however, it is important to clarify that cells containing COX1 and 
COX2 produced more PGE2 than cells containing COX3 in the 
Study Species Proposed target of ACT
Chandrasekharan et al.24 Canine (cerebral cortex)
Insect (cells)
COX3
Ayoub et al.25 Mouse COX3
Ayoub et al.26 Mouse COX3
Ayoub and Flower20 Mouse COX3 or other COX1 gene 
derived protein
Li et al.27 Mouse COX2 (febrile antipyretic)
Unclear afebrile hypothermic 
action
Hinz et al.30 Human COX2
Lee et al.48 Human COX2
TA B L E  1 Key	research	investigating	
the in vivo mechanism of action of ACT 
and its proposed target
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absence of ACT (COX1 containing cells 5- fold and COX2 contain-
ing cells 25- fold greater PGE2 production than COX3 containing 
cells24,31). Therefore, the apparent potency of ACT on COX3 may 
be a consequence of the low rate of PGE2 production by COX3.31,32 
With	only	one	study	completing	this	 type	of	analysis24 further as-
sessment of COX1- 3 sensitivity to ACT is required.31
Since the discovery of the COX3 enzyme and its apparent sen-
sitivity to ACT24 research has sought to determine if this is how 
ACT exerts its action, positing that this explains why ACT does 
not display anti- inflammatory and antiplatelet function.20,24– 26 To 
investigate this, COX3 hypothesis studies have assessed the anal-
gesic (acetic acid/iloprost induced writhing in mice) and antipyretic/
hypothermic (i.e., PGE2 inhibition) function of ACT.20,25,26,35,36 The 
writhing responses to acetic acid or iloprost injection were dose 
dependently reduced by ACT; however, diclofenac (a non- selective 
NSAID) only reduced acetic acid- induced writhing.26 Iloprost- 
induced writhing is not reduced by peripherally acting drugs like 
NSAIDS; the anti- inflammatory or antiplatelet ability of NSAIDS 
is generally a result of peripheral COX inhibition.26,37 This exhib-
its ACT’s greater central mechanism of action26,31 with the au-
thors citing COX3, only observed in the brain [i.e., centrally24], as 
the target of the analgesic effects of ACT in these mice.26 ACT is 
not only antipyretic but hypothermic [i.e., reduces afebrile core 
temperature (Tc)] in rodents and humans.25,35,36 ACT- induced afe-
brile Tc reduction appears to be a direct result of PGE2 inhibition 
in mice25 (a mechanism also hypothesized in humans but yet to be 
confirmed38,39). More recently, COX3 inhibition has been extended 
to ACT’s febrile Tc reduction,20 in contrast to previous research 
which observed COX3 to be unresponsive to acute inflammation.40 
The authors cite the loss of potent hypothermic and antipyretic ac-
tion in COX1 knockout mice20,25 and the fact that COX1 selective 
and dual COX1/2 inhibitors failed to induce afebrile hypothermia20 
as evidence of COX3 inhibition by ACT. However, the use of COX1 
knockout mice to assess the function of this COX3 enzyme may not 
be experimentally sound, as in COX1 knockout mice, gene targeting 
disrupts the C terminal of COX1.41 Any protein derived (e.g., COX3) 
from this would be without the 120 C terminal acids central to the 
enzymatic activity of COX1,41,42 but (and importantly), would con-
tain the entire sequence for the COX3 protein.41 It is improbable, 
therefore, that COX3 would be involved in prostaglandin synthesis 
for pain and/or thermoregulation.41 Indeed, evidence for COX3 as 
the target of ACT’s action is far from unequivocal. In similar exper-
iments COX3 was not found to be involved in either the antipyretic 
or hypothermic action of ACT.27 Additionally, one of the key argu-
ments for COX3 being the target of ACT is that the drugs amin-
opyrine and antipyrine, apparent COX3 selective inhibitors, elicit 
similar analgesic and antipyretic/hypothermic responses as ACT in 
mice.20,25,26 Importantly, the premise for these drugs being selec-
tive COX3 inhibitors is from the same study that first identified the 
existence of this COX3 enzyme and the potential for it to be a target 
for ACT.24 Much like ACT, these drugs (aminopyrine and antipyrine) 
are considered to be mild analgesics with weak inhibition of the 
well- recognized COX1/2 isoforms with their precise mechanism of 
action still debated.43,44
The work described here mainly details results from mamma-
lian species other than humans despite the focus of this paper is 
human in vivo physiology. Namely, human ACT/COX3 data are not 
available. It is plausible that undiscovered COX isoforms and splice 
F I G U R E  1 Schematic	of	hypothesis	1:	ACT	does	not	inhibit	a	third	cyclooxygenase	(COX3)	isoform.	Panel	(A)	The	proposed	COX3	
mechanism of action of ACT. A splice variant of COX1 named COX324 has exhibited physiological and pathological function in mice, canine, 
and insect models.20,24– 26 This is not the case in other mammals [humans/rats etc22]. Panel (B) The more traditional schematic of the 
mechanism of action of ACT. Both ACT and NSAIDS inhibit COX1/2. NSAIDS generally exhibit a more peripheral action on COX hence a high 
anti- inflammatory/antiplatelet action,26,37 whereas ACT has a more central mechanism of action and displays only analgesic and antipyretic 
function.31 On the assumption that there is no functional third COX isoform, the afebrile hypothermia and early phase febrile actions are likely 
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variants could display germane physiological functions22 neverthe-
less, the current evidence for COX3 as the elusive target of ACT are 
inconclusive:
1. COX3 protein has been detected in human tissues23 but no 
functional COX3 enzyme has been sequenced.20,32 Multiple COX 
variants have been sequenced in rodent and human models; 
however, no physiological or pathological functions have been 
ascribed to these variants and there is no evidence that they 
are a target for ACT.22,28 Indeed, ~50% of human genes may 
produce mRNA products that are unproductive targets for 
degradation.45 COX3, a splice variant of COX1, may be an 
example of one of these products.
2. The proposed evidence of COX3 as a target of ACT may not be 
experimentally sound (i.e., use of COX1 knockout mice to model 
COX3 activity/function41 and the interpretation of COX3 sensi-
tivity to ACT may be a direct consequence of low catalytic activity 
not inhibition31,32).
3. Translation of data from other mammalian species is often inap-
propriate due to large interspecies differences. There are vast 
differences across mammalian species (e.g., body size and hair 
coverage) that make the translation to humans challenging.28,46 
Furthermore, even between rodent species and different strains 
of the same species there are differences in the response to ACT 
administration.47 Indeed, the COX3 enzyme shown to exhibit 
COX activity in mice24 has been cloned in rats but does not exhibit 
COX activity.29
Based on the current evidence, we hypothesize that ACT does 
not act on COX3 (in acceptance of hypothesis i).
3  |  COX 2 SELEC TIVIT Y OF 
ACETAMINOPHEN
To the authors’ knowledge, there are two human studies that pro-
vide evidence in support of ACT as a selective COX2 inhibitor.30,48 
In vitro, ACT displayed a 4.4- fold selectivity for COX2 and in vivo 
ACT average plasma concentrations were below the IC50 value for 
COX1 but greater than or equal to the IC50 value for COX2.
30 Ex 
vivo concentrations of thromboxane B2 [TXB2 (COX1 pathway)] 
and lipopolysaccharide (LPS) induced PGE2 (COX2 pathway) repre-
sented an 83% inhibition of COX2 compared to 56% COX1.30 This 
level of COX2 inhibition is similar to that of other selective COX2 
inhibitors49; however, the 4.4- fold selectivity for COX2 over COX1 
is considerably lower than that observed in other selective COX2 
inhibitors (30– 433 fold greater inhibition of COX2 than COX150). 
Furthermore, other COX2 selective inhibitors do not exhibit such 
high COX1 inhibition; etoricoxib and celecoxib inhibited ex vivo 
TXB2 (i.e., COX1) by 15.5% (95% CI: 6.6 – 23.5) and 20.2% (95% CI: 
11.5– 28.1), respectively.51 The conclusion that the greater COX2 in-
hibition by ACT demonstrates COX2 selectivity30 is therefore some-
what questionable.
In response to a clinical model of inflammation, ACT only sup-
pressed in vivo PGE2 (and not TXB2) similar to rofecoxib (a selec-
tive COX2 inhibitor) suggesting that in vivo ACT selectively inhibits 
COX2.48 It is important to note the removal of two impacted third 
molars induces a pathophysiological state where COX2 (inducible in 
response to pathology) is likely the predominant functioning COX 
isoform.12 Similarly, in rodent models where a pathophysiological 
state (i.e., fever) is induced via LPS injection it is ACT COX2 inhibi-
tion that prevents and/or reduces high Tc resulting from LPS induced 
fever.27,52 The greater COX2 inhibition exhibited in these stud-
ies30,48 is not conclusive evidence that ACT is selective in its COX 
inhibition. Indeed, in vitro ACT can be a potent inhibitor of COX1 
when peroxide concentrations are low, although supratherapeutic 
concentrations were used.53
When	attempting	to	ascribe	COX	selectivity	to	ACT	it	is	imper-
ative to understand the biological conditions that determine COX 
activity. COX1 and COX2 oxidation of arachidonic acid occurs under 
separate conditions and has been termed the arachidonic acid rule.54 
It appears that COX1 can utilize concentrations of arachidonic acid 
>10 µM, concentrations of this magnitude only occur when arachi-
donic acid is exogenously increased in the cell whereas, concentra-
tions	≤2.5	µM	are	released	endogenously	and	COX2	has	2-	to	4-	fold	
greater activity than COX1.55– 57 At arachidonic acid concentrations 
between 50 nM and 1 µM, COX1 produces less than 25% of the 
“product” of COX2.57 Importantly, this concentration range is likely 
what is available in vivo.58 Arachidonic acid is subject to a reacyla-
tion/deacylation cycle that keeps concentrations very low59,60, likely 
to avoid cytotoxicity that can occur if concentrations exceed 50– 
100 µM in vitro59 (human plasma arachidonic acid concentrations 
can reach 500 µM59,61). There are not precise concentrations of ara-
chidonic acid that determine oxidation by COX1 or COX2.55– 57,62– 64 
Between 2.5 and 10 µM, COX1 shows greater activity in arachidonic 
acid oxidation than COX2,57 this is likely a result of COX1 requiring 
cooperative activation (higher substrate concentration, i.e., arachi-
donic acid) while COX2 does not.57 Perhaps more conceivably it 
was the specific biological in/ex vivo conditions (i.e., fever/inflam-
mation30,48) alongside a low sample size in vitro and in vivo (n = 530) 
that accounted for the observed greater inhibition of COX2. In the 
immediate response to pathological stimuli (i.e., inflammation/fever), 
there is an intense activation of phospholipases that release a burst 
of arachidonic acid beyond the threshold of COX2 utilization.54 
Therefore, COX1 may provide the immediate febrile response.54 In 
this initial stage of the febrile response, the ability of ACT to exert 
its action is likely to be diminished due to high peroxide tone.31,53 
However, as arachidonic acid concentrations fall below the thresh-
old of COX1 oxidation, COX2 becomes the isoform responsible for 
the febrile response54 and ACT potently exerts its action.31 Under 
these conditions of low concentrations of arachidonic acid the COX2 
pathway is preferred to COX164— therefore— it may seem, albeit po-
tentially incorrectly, as if ACT is selectively inhibiting COX2 (Figure 2 
depicts the COX/arachidonic acid relationship and ACT selectivity).
As discussed previously ACT can induce a hypothermic effect 
in afebrile mammals.25,35,36 Febrile increases in Tc result from PGE2 
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(the pyrogenic mediator65) upregulation from inducible COX2, in-
hibition of COX2 (e.g., ACT/NSAID) prevents PGE2 synthesis and 
reduces fever.66 Evidence of COX2 constitutive expression/func-
tion is limited14– 17 and it is unlikely that inhibition of COX2 derived 
PGE2 is responsible for the reductions in afebrile Tc following 
ACT administration observed in mice25 and humans.35,36 This hy-
pothermic effect occurs in mammals housed below their thermo-
neutral zone,25,35,36 conditions that require heat generation (i.e., 
thermogenesis) to maintain homeostatic Tc.67 In afebrile mice, ACT- 
induced Tc reductions were simultaneous with 96% reductions in 
PGE225 suggesting that PGE2 may be involved in afebrile Tc regu-
lation. Evidence of ACT inhibitory action on COX3 is equivocal and 
robustly refuted (discussed above); nevertheless, the data suggest 
inhibition of COX1 (or COX1- derived isoform) not COX2 is respon-
sible for ACT induced afebrile Tc reductions.20,25,26 In vivo analysis 
(i.e., COX/PGE2 concentrations) is required in humans to determine 
whether ACT induced COX1 inhibition is the cause of this afebrile 
hypothermic effect.
In vivo biological variations determine COX activity (i.e., COX1/2 
derived PG’s) and this appears to directly affect the potency of ACT 
and the COX isoform it inhibits; ACT can appear to be COX2 se-
lective but current evidence does not support this notion.31 Based 
on the work described here we hypothesize ACT is not selective in 
its COX inhibition (in acceptance of hypothesis ii) but subtle in vivo 
biological variations dictate the COX isoform inhibited by ACT (in 
acceptance of hypothesis iii).
4  |  PHYSIOLOGIC AL VARIATIONS 
DIC TATE ACETAMINOPHEN COX 
INHIBITION
Arachidonic acid concentrations in vivo (i.e., physiological condi-
tions) determine which COX isoform PG’s are derived from and 
subsequently influences the isoform ACT inhibits.31 ACT’s efficacy 
is increased when arachidonic acid concentrations are low, which 
are generally concomitant with low peroxide tone within cells.31 
Figure 2 represents the relationship between arachidonic acid and 
ACT potency. More potent COX1 inhibition by ACT occurs at low 
peroxide concentrations,53 and more recently, this has been ex-
tended to intact cells.68 Broken cells and/or exogenous increases in 
intracellular peroxide tone in intact cells abolish the COX inhibitory 
effects of ACT in vitro.68,69	Within	 intact	 cells	ACT	COX1	 inhibi-
tion is evidenced to occur when exogenously added arachidonic 
acid concentration is low or in the presence of cytokines (e.g., in-
terleukin 1β) that release arachidonic acid in low concentrations.69 
ACT’s efficacy is higher under these conditions because low ara-
chidonic acid concentrations result in low PGG2 (a hydroperoxide) 
within cells.31 As described, independent COX2 oxidation of arachi-
donic	acid	occurs	at	lower	concentrations	(≤2.5	µM)	than	independ-
ent COX1 oxidation (>10 µM64), giving the perception that ACT is 
COX2 selective and accounts for its lack of anti- inflammatory and 
antiplatelet activity where high concentrations of peroxides are 
present.31,69 Concentrations of arachidonic acid at COX1 oxida-
tion levels (>2.5 µM) are still considered low (i.e., not cytotoxic59) 
therefore, assuming that COX3 is not the target of ACT, the loss 
of hypothermic and analgesic properties in COX1 knockout mice, 
but not COX2 knockout mice,25,26 may evidence COX1 inhibition by 
ACT under low arachidonic acid concentration/peroxide tone condi-
tions31; however, specific human in vivo data is required to confirm 
this assertion.
Illustrated here is the intricacy of determining the specific in vivo 
action of a drug and the activity of complex molecules/biomarkers 
in mammalian species.18,19 Much of the data presented here requires 
confirmation from human in vivo research. However, we maintain 
that on current evidence it is the subtle in vivo biological variations 
that determine the COX isoform inhibited by ACT (in acceptance of 
hypothesis iii), ACT is not a selective COX2 inhibitor (in acceptance 
of hypothesis ii) and COX3 is not the target of ACT inhibition (in 
acceptance of hypothesis i).
5  |  NON-  COX- REL ATED MECHANISMS OF 
AC TION
The main focus of this article is the COX– ACT- related mechanism 
of action; however, it is important to acknowledge recent evidence 
that suggests the analgesic effects exhibited by ACT may be a re-
sult of action via non- COX- related pathways [for a more in- depth 
review see Ohashi and Kohno70]. In brief, transient receptor poten-
tial vanilloid 1 (TRPV1) and cannabinoid 1 (CB1) receptors are in-
volved in pain modulation.71,72 TRPV1 in the dorsal raphe nucleus71 
and both TRPV1 and CB1 in the rostral ventromedial medulla.72 
Activation of the TRPV1/CB1 receptors in these regions induce an-
algesia.70 ACT is metabolized to p- aminophenol that is converted to 
N- acylphenolamine (AM404) once it crosses the blood- brain bar-
rier.73 AM404 is known to act on TRPV1 and CB1 receptors,73 ac-
tion that has recently been observed to produce analgesia.70,74 This 
ACT, AM404 and TRPV1/CB1 receptor pathway appears to have a 
significant role in the analgesic effects of ACT and proffers an expla-
nation to its central prolonged mechanism of action.70 In addition, 
ACT has been cited to activate the serotonergic inhibitory pathway, 
a pathway also known to be important in the modulation of pain.75 
Inhibition of serotonergic receptors (those implicated: serotonin [5- 
HT]1A, 5- HT3, and 5- HT7) has been shown to eradicate any analgesic 
action of ACT76– 83 and reductions in serotonin levels reduces the 
analgesic efficacy of ACT.84 ACT- induced activation of this pathway 
does not, however, elucidate the analgesic mechanism of action as 
it has been shown that ACT lacks any affinity to serotonergic recep-
tors.85 How ACT interacts with this serotonergic pathway is not yet 
confirmed. Further research exploring the nuances of COX and non- 
COX- related ACT mechanisms of action are evidently required. Such 
data may also shed light on the COX- PGE2- ACT mechanisms of ac-
tions discussed above.
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6  |  RECOMMENDATIONS FOR FUTURE 
RESE ARCH
The hypotheses of this paper require further exploration. Despite dec-
ades of research, the precise mechanism of action and/or pharmaco-
logical target of ACT is still not fully understood.20,21	We	hypothesize	
that COX3 is not the target of ACT’s action; however, it is possible 
that an unidentified COX isoform or splice variant may be the target 
of ACT.22 Identification of the pharmacological target of ACT repre-
sents the possibility of alternative methods to pharmacologically treat 
pain and/or fever.20,21 Specific in vivo human research is required, 
due to the discussed issues with translation of data from rodents to 
humans.28,46 The evidence available does not support the notion that 
ACT selectively inhibits COX2; however, it may predominantly inhibit 
COX2 based on the subtle in vivo biological conditions (i.e., arachi-
donic acid/peroxide tone concentrations) that favor ACT COX2 in-
hibition. Much of the research presented focuses on acute doses of 
ACT to determine mechanism of action. Understanding the nuances 
of chronic ACT use and COX inhibition is a prevalent research ques-
tion. Prolonged COX2 inhibition poses a cardiovascular risk, chronic 
use of NSAIDs, and selective COX2 inhibitors have exhibited this side 
effect86 leading to the withdrawal of rofecoxib (COX2 selective) from 
the market.87 The risk of cardiovascular adverse events from ACT use 
is debated88; however, there is some evidence of a dose- response 
relationship with increased cardiovascular adverse events.89 Further 
investigation is required to elucidate potential ACT cardiovascular risk. 
This paper presents strong evidence that the COX isoform inhibited by 
ACT is dependent on subtle biological variations in vivo. Given there 
is no definitive consensus of how ACT induced COX inhibition occurs, 
further research is required specifically focusing on the biological con-
ditions that may alter ACT efficacy and COX inhibition.
7  |  CONCLUSION
Despite being in use as early as the 1890s (more commonly from the 
1950s) and becoming one of the most prevalently used analgesic/an-
tipyretic drugs worldwide the specific mechanism of action of ACT 
is not fully elucidated. Research attempting to discern its mechanism 
of action have been collated within this paper and based on current 
work this paper accepts the hypotheses that ACT: (i) does not act 
on a third COX isoform; (ii) is not selective in its COX inhibition; and 
(iii) inhibition of COX isoforms is determined by subtle and nuanced 
biological variations. Importantly, there is a need for further robust 
research designs to confirm these hypotheses conclusively.
8  |  NOMENCL ATURE OF TARGETS AND 
LIGANDS
Key protein targets and ligands in this article are hyperlinked 
to corresponding entries in http://www.guide topha rmaco logy.
org, the common portal for data from the IUPHAR/BPS Guide to 
PHARMACOLOGY,90 and are permanently archived in the Concise 
Guide to PHARMACOLOGY 2019/20.91
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